IQ4I's In-Vitro Diagnostics Global Market - Forecast to 2020
- Sep. 5, 2014 - VICTORIA, U.K. -- IQ4I Research & Consultancy published a new report on “In-Vitro Diagnostics (IVD) Global Market – Forecast To 2020”
analyzes and studies the major market drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific and Rest of the World.Report contains 95 market data tables and 23 figures spread through 239 pages and an exhaustive TOC on “
In-Vitro Diagnostics (IVD) Global Market[Products (Instruments, Reagents, Services & Data Management Systems), Techniques (Immunology, Point-Of-Care, Molecular Diagnostics, Haematology, Coagulation, Microbiology, and Other Clinical Instruments)
& Applications (Diabetes, Oncology, Cardiology, Sexually Transmitted Diseases, Autoimmune Disease, Nephrology, and Drug Testing)], End Users (Hospitals, Laboratories, Patient Self Testing, Point-of-Care Testing, Academics and Others)] – Forecast to 2020”.
Early buyers will receive 10% customization of your requirements.
The global IVD market is expected to grow at high CAGR values by 2020 as per IQ4I Research & Consultancy’
s new Report. The overall IVD market is expected to reach $88.0 billion by 2020 and is mainly driven by factors such as increase in incidences of chronic and infectious diseases across all age cohorts, genetic diseases, aging population, rising acceptance of personalized medicine, rise in healthcare awareness in patients and high unmet medical needs in diagnosing diseases. Screening initiatives and high investment in healthcare infrastructures mainly contributes to market growth, However factors such as difficulty in rendering rapid diagnostic results, stringent regulatory policies, reimbursement issues and economic crisis are the major restraints.
In 2013, the North America accounted for the largest share of 43.4% in 2013 of the global IVD market. However, Asia-Pacific region is expected to grow at a faster pace by 2020, due to the economic growth, the increasing number of chronic diseases, and rising awareness about the use of IVD tests to control the spread of diseases. Moreover, the matured markets, economic slowdown, competition in pricing, will compel manufacturers to focus on emerging economies.
Roche diagnostics (Basel, Switzerland)
is the largest player in the IVD market with a share of XX%, followed by Becton Dickinson and Company (U.S.) and Abbott Laboratories, who hold XX% and XX% respectively. The IVD market is consolidated, with major players accounting for approximately 70% market share in 2013. Top ten major players are Roche Diagnostics (Switzerland)
, Siemens Healthcare (Erlangen, Germany), Abbott (Abbott
Park, Illinois), Johnson and Johnson(New Jersey), Beckman Coulter(Massachusetts)
, BioMerieux (France), Bayer Healthcare (Germany), Sysmex (U.S.) and Bio-Rad (California)
. Key players such as Thermo Fisher Scientific, Inc., QIAGEN N.V., and ARKRAY, Inc. have established new manufacturing facilities and R&D units in China to grow in IVD market.